Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Ultomiris 300 mg/3 mL concentrate for solution for infusion {equilateral_black_triangle}

Active Ingredient:
ravulizumab
Company:  
Alexion Pharma UK Ltd See contact details
ATC code: 
L04AA43
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) User Manual Risk Materials HCP Med Info
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Ultomiris Patient Alert card

Important Safety Information for Patients Receiving Ultomiris® Show this card to any doctor involved in your care.

{pdf_link}

Ultomiris Patient/Parent/Legal Guardian Guide

This guide is for the parents/legal guardians of young children and Infants treated with ravulizumab. This parent information brochure is a supportive document specifically developed in order to describe the symptoms and steps for early detection and management of meningococcal infections in infants and young children. The primary source of information for patients is within the patient guides.

{pdf_link}

Ultomiris Physician's Guide

{healthcare_pro_orange} For Healthcare Professionals

Important risk minimisation information for patients with Paroxysmal Nocturnal Haemoglobinuria (PNH), Atypical Haemolytic Uremic Syndrome (aHUS), Generalised Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD).

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Alexion Pharma UK Ltd
Company image
Address
2 Pancras Square, London, N1C 4AG, UK
Telephone
+44 (0) 208 744 6600
Fax
+44 (0) 20 8744 6630
Medical Information Direct Line
0800 028 4394
Medical Information e-mail
[email protected]
Customer Care direct line
0800 1300 212